Anyue Yin1,2,3, Dewei Shang4, Yuguan Wen4, Liang Li1,2,3, Tianyan Zhou1,2,3, Wei Lu5,6,7,8. 1. School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China. 2. Peking University/Pfizer Pharmacometrics Education Center, Peking University Health Science Center, Beijing, 100191, China. 3. State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, 100191, China. 4. Guangzhou Brain Hospital (Guangzhou Huiai Hospital, the Affiliated Brain Hospital of Guangzhou Medical University), Guangzhou, 510370, China. 5. School of Pharmaceutical Sciences, Peking University, Beijing, 100191, China. luwei_pk@bjmu.edu.cn. 6. Peking University/Pfizer Pharmacometrics Education Center, Peking University Health Science Center, Beijing, 100191, China. luwei_pk@bjmu.edu.cn. 7. State Key Laboratory of Natural and Biomimetic Drugs, Peking University, Beijing, 100191, China. luwei_pk@bjmu.edu.cn. 8. Beijing Institute for Brain Disorders, Beijing, 100088, China. luwei_pk@bjmu.edu.cn.
Abstract
PURPOSE: The aim of this study was to build an eligible population pharmacokinetic (PK) model for olanzapine in Chinese psychotic patients based on therapeutic drug monitoring (TDM) data, with assistance of meta-analysis, to facilitate individualized therapy. METHODS: Population PK analysis for olanzapine was performed using NONMEM software (version 7.3.0). TDM data were collected from Guangzhou Brain Hospital (China). Because of the limitations of TDM data, model-based meta-analysis was performed to construct a structural model to assist the modeling of TDM data as prior estimates. After analyzing related covariates, a simulation was performed to predict concentrations for different types of patients under common dose regimens. RESULTS: A two-compartment model with first-order absorption and elimination was developed for olanzapine oral tablets, based on 23 articles with 390 data points. The model was then applied to the TDM data. Gender and smoking habits were found to be significant covariates that influence the clearance of olanzapine. To achieve a blood concentration of 20 ng/mL (the lower boundary of the recommended therapeutic range), simulation results indicated that the dose regimen of olanzapine should be 5 mg BID (twice a day), ≥ 5 mg QD (every day) plus 10 mg QN (every night), or >10 mg BID for female nonsmokers, male nonsmokers and male smokers, respectively. CONCLUSION: The population PK model, built using meta-analysis, could facilitate the modeling of TDM data collected from Chinese psychotic patients. The factors that significantly influence olanzapine disposition were determined and the final model could be used for individualized treatment.
PURPOSE: The aim of this study was to build an eligible population pharmacokinetic (PK) model for olanzapine in Chinese psychoticpatients based on therapeutic drug monitoring (TDM) data, with assistance of meta-analysis, to facilitate individualized therapy. METHODS: Population PK analysis for olanzapine was performed using NONMEM software (version 7.3.0). TDM data were collected from Guangzhou Brain Hospital (China). Because of the limitations of TDM data, model-based meta-analysis was performed to construct a structural model to assist the modeling of TDM data as prior estimates. After analyzing related covariates, a simulation was performed to predict concentrations for different types of patients under common dose regimens. RESULTS: A two-compartment model with first-order absorption and elimination was developed for olanzapine oral tablets, based on 23 articles with 390 data points. The model was then applied to the TDM data. Gender and smoking habits were found to be significant covariates that influence the clearance of olanzapine. To achieve a blood concentration of 20 ng/mL (the lower boundary of the recommended therapeutic range), simulation results indicated that the dose regimen of olanzapine should be 5 mg BID (twice a day), ≥ 5 mg QD (every day) plus 10 mg QN (every night), or >10 mg BID for female nonsmokers, male nonsmokers and male smokers, respectively. CONCLUSION: The population PK model, built using meta-analysis, could facilitate the modeling of TDM data collected from Chinese psychoticpatients. The factors that significantly influence olanzapine disposition were determined and the final model could be used for individualized treatment.
Entities:
Keywords:
Model-based meta-analysis; Olanzapine; Population pharmacokinetic model; Psychotic; Therapeutic drug monitoring
Authors: W L Macias; R F Bergstrom; B J Cerimele; K Kassahun; D E Tatum; J T Callaghan Journal: Pharmacotherapy Date: 1998 Nov-Dec Impact factor: 4.705
Authors: Adrienne C Lahti; Martin A Weiler; Deborah R Medoff; Carol A Tamminga; Henry H Holcomb Journal: Psychiatry Res Date: 2005-05-30 Impact factor: 3.222
Authors: Vidya Perera; Annette S Gross; Thomas M Polasek; Yan Qin; Gauri Rao; Alan Forrest; Junzhe Xu; Andrew J McLachlan Journal: Expert Opin Drug Metab Toxicol Date: 2013-05-04 Impact factor: 4.481
Authors: Thomas M Polasek; Geoffrey T Tucker; Michael J Sorich; Michael D Wiese; Titus Mohan; Amin Rostami-Hodjegan; Porntipa Korprasertthaworn; Vidya Perera; Andrew Rowland Journal: Br J Clin Pharmacol Date: 2018-01-11 Impact factor: 4.335